Mina, R., Musto, P., Rota-Scalabrini, D., Paris, L., Gamberi, B., Palmas, A., Aquino, S., de Fabritiis, P., Giuliani, N., De Rosa, L., Gozzetti, A., Cellini, C., Bertamini, L., Capra, A., Oddolo, D., Vincelli, I. D., Ronconi, S., Pavone, V., Pescosta, N., Cea, M., Fioritoni, F., Ballanti, S., Grasso, M., Zamagni, E., Belotti, A., Boccadoro, M., & Gay, F. (2023). carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet oncology, 24(1), 64–76. http://access.bl.uk/ark:/81055/vdc_100173693287.0x000010